Nano Dimension adds Nadav Kidron to board; Infinite Epigenetics exclusivity lapses without deal

Nano Dimension Ltd.

Nadav Kidron appointed to Nano Dimension board as Class II independent director, effective Aug 16, 2026; joins Audit and Compensation committees.
Kidron is CEO of Oramed Pharmaceuticals (ORMP) since 2006; also director at Lifeward (LFWD) and Alpha Tau (DRTS).
30-day exclusivity period under non-binding term sheet with Infinite Epigenetics expired July 15, 2026; no definitive agreement reached.
As of Aug 16, 2026, parties have not reached agreement on definitive terms; no further details disclosed.

item 5.02 item 7.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Nadav Kidron

Class II director

NNDM · Nano Dimension Ltd.

Effective: 2026-08-16
Filed: August 18, 2026, 8:00 AM ET

On August 16, 2026, the Board of Directors (the “Board”) of Nano Dimension Ltd. (the “Company”) appointed Nadav Kidron to the Board as a Class II director for the term expiring on the date of the annual meeting of the stockholders to be held in 2026 and until his successor is duly elected and qualified, or until his earlier resignation or removal, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nadav Kidron was appointed as Class II director at Nano Dimension Ltd..

Action: appointed
Role: Class II director

Exact text from the filing

On August 16, 2026, the Board of Directors (the “Board”) of Nano Dimension Ltd. (the “Company”) appointed Nadav Kidron to the Board as a Class II director for the term expiring on the date of the annual meeting of the stockholders to be held in 2026 and until his successor is duly elected and qualified, or until his earlier resignation or removal, effective immediately.

View on SEC.gov

Nano Dimension Ltd. filing history →

Source: SEC EDGAR

accession 0001193125-26-354738

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.